Comparative Pharmacology
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE.
MECLOFENAMATE SODIUM vs PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Propoxyphene is a centrally acting opioid analgesic that binds to mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant that may enhance analgesia.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
1-2 capsules orally every 4-6 hours as needed; maximum 6 capsules per day. Each capsule contains propoxyphene hydrochloride 65 mg, aspirin 325 mg, and caffeine 32.4 mg.
None Documented
None Documented
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Propoxyphene: 6-12 hours (up to 36 hours in overdose); norpropoxyphene: 30-36 hours. Aspirin: 2-3 hours for low doses, up to 15-30 hours in overdose. Caffeine: 3-6 hours; prolonged in liver disease.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal elimination of propoxyphene and its metabolites (mainly norpropoxyphene) accounts for approximately 70-90% of the dose; fecal excretion is minimal (<10%). Aspirin is renally eliminated as salicylates (75-90% as conjugates, 10% free), while caffeine is primarily metabolized and its metabolites are excreted renally.
Category C
Category D/X
NSAID
NSAID / Antiplatelet